Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed the qualifying DM-230 trial~* If females of child-bearing potential, subjects must be using adequate contraception~* Provide written informed consent~* Be willing and able to comply with scheduled study visits, treatment plan, lab tests and other study procedures~* Be greater than 80% compliant in study medication use during the last three visits for DM-230~Exclusion Criteria:~* Subjects who have developed one or more morbidities during the DM-230 trial that would pose a safety concern

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 16-Week population (Type: EXPERIMENTAL): Placebo subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
- 72-Week population (Type: EXPERIMENTAL): Active treatment subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)

Based on this trial design, predict the completion outcome and termination type (if applicable).